Adaptimmune Therapeutics 2021 Annual Report 10-K

Adaptimmune Therapeutics PLC filed its 2021 Form 10-K annual report covering operations for the fiscal year ended December 31, 2021. The UK-based immunotherapy company, trading on Nasdaq under ticker ADAP, discloses financial condition, risk factors, and strategic developments in its cell therapy platform.